



## **Ventripoint Appoints MediTek Lifesciences LLC as Distributor for California**

**Toronto, Ontario – The Newswire – November 17, 2022** - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) who's mission is to improve cardiac diagnostic for everyone, everywhere and especially for children, is pleased to announce that it has appointed MediTek Lifesciences LLC. (Meditek) as a distributor for the USA-California market. MediTek distributes products specific to cardiology research and treatment centers throughout the State of California, USA.

"It is appropriate that the first distributor in the USA is for California, the most populous state in the USA, which is a strategic starting point for the VMS+ family of products to address the heart healthcare needs of the approximately 39 million residents in the state," commented Dr. George Adams, Ventripoint's CEO.

California's economy is poised to be the 4<sup>th</sup> largest in the world (<https://www.bloomberg.com/opinion/articles/2022-10-24/california-poised-to-overtake-germany-as-world-s-no-4-economy>), California has a number of leading cardiac centers and is an excellent base to begin to advance cardiac diagnostics in the USA.

MediTek has multiple sales representatives with a combined experience of over 45 years in the cardiology sector within the Californian market and understand how the VMS+ meets doctors' needs by providing reliable echocardiography measurements. The representatives have completed training and their initial focus will be the clinicians and cardiologists who treat patients with congenital heart disease, which is a life-long condition where accurate regular assessments of right-heart function are critical to the planning and monitoring of appropriate care. With an established customer base of more than 100 clinical sites, MediTek will grow Ventripoint's awareness within the California market and further expand its customer base.

### **About Ventripoint Diagnostics Ltd.**

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams  
[gadams@ventripoint.com](mailto:gadams@ventripoint.com)  
519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

### **Forward Looking Statements**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com). Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.